High Yield Markets
  • World News
  • Politics
  • Investing
  • Stock
  • Editor’s Pick
Editor's PickInvesting

Trump Attempts Price Controls on Prescription Drugs

by May 12, 2025
May 12, 2025

Michael F. Cannon

medicaid, subsidies

I’m usually the guy reminding everybody, “It is not a ‘price control’ when the government reduces the prices [it] pays for drugs.” I expected that I would be singing that tune again this morning when President Trump released an executive order on drug pricing. To my knowledge, Trump has never taken any steps to impose actual price controls on prescription drugs (read: coercive restraints on pharmaceutical transactions outside of government programs). 

I was wrong. Unlike the Inflation Reduction Act or Trump’s past proposals, Trump’s executive order is an attempt to impose government price controls on pharmaceuticals.

Today, President Trump ordered the Department of Health and Human Services to “communicate…price targets to pharmaceutical manufacturers.” Trump does not in any way suggest those price targets would apply only to the prices the government pays for medicines. 

If HHS determines that pharmaceutical manufacturers have failed to make “significant progress” (whatever that means) toward those targets, things get ugly. In that event, Trump commands:

  • HHS shall “to the extent consistent with law…impose most-favored-nation pricing.”
  • The Department of Justice and the Federal Trade Commission “shall…undertake enforcement action against any anti-competitive practices.” 
  • The Commerce Department and other agencies “shall…consider all necessary action regarding the export of pharmaceutical drugs or precursor material.”
  • The Food and Drug Administration shall “review and potentially modify or revoke approvals granted for drugs.”
  • All federal agencies shall “take all action available…to address global freeloading and price discrimination against American patients.” 

Trump’s executive order is a laundry list of coercive actions he plans to take against drug companies that do not make “significant progress” toward his “price targets.” 

HHS does not have the power to “impose” price controls on private pharmaceutical purchases. If it did, some past administration already would have exercised that authority. But Trump might be able to impose price controls even without statutory authority. Congress has granted the executive branch so much power already, and so much discretion in using those powers, that the president may be able to claim this power that Congress never granted. What drug manufacturer would risk having HHS, DOJ, the FTC, Commerce, the FDA, and other federal agencies simultaneously taking action against them? 

The federal government does countless things that increase prices for pharmaceuticals. If Trump wants to reduce drug prices, there are several steps he can take and steps that he should push Congress to take. Price controls are never the answer. 

If Trump were serious about reducing drug prices, for example, he could unilaterally implement what I recommended late last year: “The administration should expand Executive Order 13938 [from July 2020] by directing the secretary to finalize a regulation that waives the prohibition on reimportation for all classes of drugs and devices from all Organisation for Economic Co-operation and Development member nations.” That one measure would reduce the trade barrier that enables the very price discrimination that vexes Trump. Instead, Trump lamely directs the HHS Secretary to “consider” allowing more reimportation, after which he could maybe ask the FDA “to describe circumstances” under which US residents could “import prescription drugs” but only “on a case-by-case basis.” 

previous post
Missouri Senator Josh Hawley Calls for a Vote on His PELOSI Act – Preventing Elected Leaders from Owning Securities and Investments
next post
Episcopal Church Ends Refugee Partnership with U.S. Government — Cites Moral Opposition to Resettling Persecuted White Afrikaners from South Africa

You may also like

Can the White House Denaturalize Domestic Opponents?

July 25, 2025

An Updated Interview with George Selgin on Free...

July 25, 2025

Inflation Can Increase Capital Gains Tax Rate to...

July 25, 2025

Friday Feature: Edefy, “Pod Schooling Made Simple”

July 25, 2025

Yiwu: China’s Free-Market City

July 25, 2025

Man Admits to Medicaid Fraud—That’s Not the Worst...

July 25, 2025

States Are Streamlining Licensing—ICE Is Kicking In Windows

July 24, 2025

Learning from the Caribbean CBDC Experience

July 24, 2025

Fifteen Years of Dodd-Frank: A Legacy of Missed...

July 23, 2025

July 30 Event: Senators Tim Kaine and Rand...

July 23, 2025
Join The Exclusive Subscription Today And Get Premium Articles For Free


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Recent Posts

  • Can the White House Denaturalize Domestic Opponents?

    July 25, 2025
  • An Updated Interview with George Selgin on Free Banking and Bitcoin

    July 25, 2025
  • Inflation Can Increase Capital Gains Tax Rate to Infinity

    July 25, 2025
  • Friday Feature: Edefy, “Pod Schooling Made Simple”

    July 25, 2025
  • Yiwu: China’s Free-Market City

    July 25, 2025
  • About Us
  • Contacts
  • Privacy Policy
  • Terms and Conditions
  • Email Whitelisting

Copyright © 2025 highyieldmarkets.com | All Rights Reserved

High Yield Markets
  • World News
  • Politics
  • Investing
  • Stock
  • Editor’s Pick